**Core tip:** In this single centre, retrospective study we compared the incidence of observed delayed graft function (DGF) in 247 consecutive kidney transplant recipients with the predicted risk of DGF according to 3 different nomograms. Although the Irish nomogram provided an acceptable predictive value for the global study population, this calculator did not allow to make an accurate prediction of DGF at the individual level. Our study suggests that currently available predictive models for the risk of DGF after kidney transplantation are predictive in the population in which they were derived, but they lose their predictive value in external validations.

INTRODUCTION
============

Delayed graft function (DGF) is classically defined as the need for at least one postoperative dialysis session during the first week after transplantation\[[@B1],[@B2]\]. This definition has some limitations since the postoperative requirement of dialysis is not standardized and the decision to dialyze is subjective. For this and other reasons, the frequency of DGF varies worldwide between 10% and 40% for deceased donor kidney transplants\[[@B1],[@B3]\]. DGF leads to prolonged hospitalization, higher cost of transplantation, and increased complexity of management of immunosuppressive drugs\[[@B4]-[@B6]\]. DGF is associated with an increased risk of acute rejection and may negatively impact long-term allograft function and outcome\[[@B7],[@B8]\].

There are currently neither clinical practice guidelines nor an approved therapy to prevent DGF. In addition, the use of "extended criteria donors" (ECD) and kidneys from donors after cardiac death (DCD), which are associated with a higher incidence of DGF, is rising. The ability to predict DGF at the time of the transplant offer might help in clinical decisions making, such as declining the offer, selecting a recipient who would have a lower DGF risk, or modifying the transplantation strategy. This may include efforts to shorten the cold ischemia time (CIT), or delay the initiation of calcineurin inhibitors (CNIs) under the cover of induction therapy with anti-lymphocyte antibodies, or even to machine-perfuse the kidney.

Recently several DGF-scoring systems have been developed. In 2003, Irish et al\[[@B6]\], using a combination of 16 donor- and recipient-related risk factors known at the time of transplantation, developed a nomogram to predict/quantify the risk of DGF after renal transplantation. In 2010 they refined their previously published model using a more recent data set and adding two risk factors (in total 18) to the analysis (Table [1](#T1){ref-type="table"})\[[@B9]\]. This predictive model has an area under the receiver operating characteristic curve (ROC AUC) of 0.70, which indicates a good degree of discrimination\[[@B9]\]. In 2009, Jeldres et al\[[@B10]\] developed a simpler but equally accurate scoring system on 532 patients (6 variables, AUC = 0.74) (Table [1](#T1){ref-type="table"}). More recently Chapal et al\[[@B11]\] proposed a predictive score that could be calculated by computing only 5 variables with a ROC AUC of 0.73 (Table [1](#T1){ref-type="table"}).

###### 

Comparison of variables used in different scoring systems

                                                  **DGF risk calculator (Irish et al\[[@B9]\])**   **DGFS scoring system (Chapal et al\[[@B11]\])**   **Jeldres scoring system (Jeldres et al\[[@B10]\])**
  ----------------------------------------------- ------------------------------------------------ -------------------------------------------------- ------------------------------------------------------
  Recipient variables                                                                                                                                 
  Recipient BMI                                   \+                                               \+                                                 \-
  Recipient age                                   \+                                               \-                                                 \+
  No. of HLA mismatches                           \+                                               \-                                                 \+
  Peak PRA (%)                                    \+                                               \-                                                 \+
  Recipient race                                  \+                                               \-                                                 \-
  Recipient gender                                \+                                               \-                                                 \-
  Duration of dialysis                            \+                                               \-                                                 \-
  History of diabetes mellitus                    \+                                               \-                                                 \-
  Previous transplantation or blood transfusion   \+                                               \-                                                 \-
  Single or multiple organ transplant             \+                                               \-                                                 \-
  Recipient weight                                \-                                               \-                                                 \+
  Donor variables                                                                                                                                     
  Donor age                                       \+                                               \+                                                 \+
  Duration of CIT                                 \+                                               \+                                                 \+
  Terminal serum creatinine                       \+                                               \+                                                 \-
  Donor weight                                    \+                                               \-                                                 \-
  Primary cause of death                          \+                                               \-                                                 \-
  History of hypertension                         \+                                               \-                                                 \-
  Duration of WIT                                 \+                                               \-                                                 \-
  Type of the donor (living, DCD)                 \+                                               \-                                                 \-
  Type of induction therapy                       \-                                               \+                                                 \-

PRA: Panel-reactive antibody; WIT: Warm ischemia time; CIT: Cold ischemia time; DCD: Donation after cardiac death; DGF: Delayed graft function.

The main aim of our study was to conduct a single-center retrospective analysis of a cohort of 247 adult patients to evaluate the performance of available nomograms to predict DGF in our patients, *i.e*., in a different population than the one they have been tested in. We also studied separately recipients of standard criteria, extended criteria and donation after cardiac death donors.

MATERIALS AND METHODS
=====================

Patient characteristics
-----------------------

From January 1^st^ 2003 to December 31^st^ 2012, 349 renal transplantations were performed at the Antwerp University Hospital. Data were collected from our prospective institutional database and the database of Eurotransplant International Foundation. We excluded 27 pediatric transplants (aged \< 18), 16 combined solid organ transplantations in adults (13 pancreases and 3 hearts), 31 transplantations performed with living donors (10.1%), 2 pre-emptive transplantations and 15 machine perfused kidneys. Moreover, we excluded 5 patients because of missing data for CIT. Thus, a total of 253 kidney transplantations from a deceased donor (87% first and 13% re-grafts), performed on 243 patients were considered for study. Six out of those 253 grafts (2%) were lost due to primary non function (PNF). These patients were excluded from further analysis and the final data set comprised 247 transplantations. Recipient and donor characteristics at the time of transplantation are summarized in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

###### 

Recipient characteristics at the time of transplantation

  --------------------------------------------------------------- --------------------------------------------------
  Age (yr)                                                        50.2 ± 11.9[2](#T2FN2){ref-type="table-fn"}
  Origin (%)                                                      
  Blacks                                                          4.5
  Caucasians                                                      95.5
  Gender (%)                                                      
  Male                                                            61.9
  History of diabetes mellitus (%)                                
  Yes                                                             16.6
  Body mass index (kg/m²)                                         25.1 ± 3.8[2](#T2FN2){ref-type="table-fn"}
  Pretransplant transfusions (%)                                  
  Yes                                                             38.1
  No                                                              56.7
  Unknown                                                         5.3
  Duration of the pre-transplant renal replacement therapy (mo)   26.7 (16.4-43.5)[1](#T2FN1){ref-type="table-fn"}
  Peak panel-reactive antibodies (%)                              88.5
  ≤ 5%                                                            9.5
  5%-80%                                                          2
  ≥ 80%                                                           
  Proportion of kidney re-graft (%)                               12.6
  Total HLA mismatches                                            3 (2-3)[1](#T2FN1){ref-type="table-fn"}
  --------------------------------------------------------------- --------------------------------------------------

Median with P25-75;

Mean ± standard deviation (SD).

###### 

Donor characteristics at the time of transplantation

  ------------------------------------ --------------------------------------------------
  Age (yr)                             45.1 ± 14.1[2](#T3FN2){ref-type="table-fn"}
  Weight (kg)                          76.2 ± 16.4[2](#T3FN2){ref-type="table-fn"}
  History of hypertension (%)          
  Yes                                  23.1
  No                                   74.5
  Unknown                              2.4
  Terminal serum creatinine (mg/dL)    0.78 (0.61-1.00)[1](#T3FN1){ref-type="table-fn"}
  Donor type (%)                       
  Standard criteria donor              68.8
  Extended criteria donor              17
  Donation after cardiac death donor   14.2
  Primary cause of death (%)           
  Cerebrovascular accident/stroke      27.1
  Anoxia                               8.1
  Other                                64.8
  Cold ischemia time (h)               14 ± 4.7[2](#T3FN2){ref-type="table-fn"}
  Second warm ischemia time (min)      32.8 ± 7.9[2](#T3FN2){ref-type="table-fn"}
  ------------------------------------ --------------------------------------------------

Median with P25-75;

Mean ± standard deviation (SD).

Definition of DGF, PNF and ECD
------------------------------

DGF was defined as the requirement of at least one dialysis within the first 7 d post-transplantation. The duration of DGF was defined as the number of days between the transplantation and the day of the last dialysis. PNF was defined as the absence of allograft function starting immediately after transplantation, and requiring maintenance dialysis. An ECD was defined as: A donor aged ≥ 60 years, or a donor aged 50-59 years with at least 2 of the following conditions: History of hypertension, terminal serum creatinine level greater than 1.5 mg/dL, or death resulting from a cerebrovascular accident/stroke (CVA).

Post-transplant immunosuppressive therapy
-----------------------------------------

One hundred and sixty-one patients (63.6%) were given an induction with an inhibitor of the IL2-receptor (basiliximab of daclizumab). Ninety-two patients (36.4%) were induced with antithymocyte globulin (ATG). According to our induction immunosuppression protocols ATG was given to immunized patients (peak PRA \> 50%), patients of North-African origin, patients with a history of acute rejection during the first year after previous transplantation or in the case of kidney transplantation with ECD or DCD donor kidneys. Most patients (*n* = 244, 96.4%) received a CNI as initial therapy in addition to the treatment with corticosteroids and mycophenolate mofetil. Cyclosporin A was initiated at a starting dose of 2 × 4 mg/kg at post-transplant day 1. Only 7 patients (2.8%) were given mTOR-inhibitors. Two remaining patients (0.8%) \[Eurotransplant Senior Program (ESP)\] did not receive either medication but only ATG, MMF and prednisolone.

Data collection and DGF risk assessment
---------------------------------------

Risk factors for DGF included donor\[[@B12]-[@B15]\] and recipient factors known before and at the time of the transplantation and were required to calculate the risk of DGF with the DGF risk calculator\[[@B9]\] ([www.transplantcalculator.com/DGF](www.transplantcalculator.com/DGF)), the Jeldres scoring system (Jeldres et al\[[@B10]\]) and the DGFS scoring system\[[@B11]\]. Recipient variables included: Age, gender, race, body mass index (BMI), history of diabetes mellitus, previous transplantation, pretransplant blood transfusion, duration of renal replacement therapy (RRT), the percentage of serum panel-reactive antibodies (peak PRA), and the number of HLA mismatches. Donor variables included: Age, gender, weight, donor type \[standard criteria donor (SCD), ECD, DCD\], primary cause of death, history of hypertension, duration of cold (CIT) and second warm ischemia time (WIT), and the terminal serum creatinin (mg/dL).

Statistical analysis
--------------------

The statistical methods were performed and reviewed by Kristien Wouters (Department of Medical Statistics, Antwerp University Hospital, B-2650 Edegem, Belgium) and by Erik Fransen (StatUa Center for Statistics, University of Antwerp, B-2610 Wilrijk, Belgium).

Normality was tested with the Shapiro-Wilk and the Q-Q plot test. Normally distributed data are represented as mean and standard deviation; non-normally distributed data as median with P25 and P75. Categorical data are presented as numbers and percentages. Comparison of predicted DGF probability between DGF positive and negative patients was done by means of the Mann-Whitney *U* test. Receiver operating characteristic (ROC) curves were generated to evaluate the performance of explanatory scoring systems in predicting outcomes. The c-statistic (or AUC = area under ROC curve) was used as a measure of the predictive performance of the studied scoring systems. Additionally, the performance of the 3 nomograms was evaluated using a Hosmer-Lemeshow goodness-of-fit test. All data were analyzed using IBM SPSS statistics (version 21). Statistical significance was predefined as a *P*-value \< 0.05. Goodness-of-fit was set at *P* \> 0.05 for the Hosmer-Lemeshow test.

RESULTS
=======

DGF occurred in 38 of the 247 transplants under study (15.3%). The mean duration of DGF was 11.3 ± 15.1 d (range 1-71 d). Graft survival at one year was comparable in patients with or without DGF (94.6% *vs* 93.3% respectively, *P* = ns). However, graft function was significantly inferior in patients with DGF both at 30 d (creatinine clearance according to MDRD formula 31 ± 16 mL/min *vs* 46 ± 17 mL/min, *P* = 0.001) and at 1 year (42 ± 14 mL/min *vs* 52 ± 17 mL/min, *P* \< 0.001).

Analysis according to the algorithm of Irish et al\[[@B9]\]
-----------------------------------------------------------

At the population level, the average DGF risk calculated with the DGF risk calculator was 18.5%, which was close to the observed data (DGF rate: 15.3%). The AUC was 0.69 (Figure [1](#F1){ref-type="fig"}). Figure [2A](#F2){ref-type="fig"} illustrates the relatively good calibration of the Irish model. The predicted DGF risk and the observed DGF probabilities were close (*P* = 0.74, Hosmer-Lemeshow statistic). The mean calculated DGF risk was significantly different (*P* \< 0.0001) between DGF-positive and DGF-negative subjects (Figure [3](#F3){ref-type="fig"}). However, at the level of the individual patient the calculated risk of DGF overlapped very widely (Figure [3](#F3){ref-type="fig"}). Indeed, it ranged from 10% to 51% for recipients with DGF and from 4% to 56% for those without DGF. The sensitivity, specificity and positive predictive value of a calculated DGF risk ≥ 30% were 32%, 91% and 38% respectively.

![Receiver operating characteristic curves to evaluate the prognostic capacity of cold ischemia time, the delayed graft function risk calculator, the Jeldres scoring system\[[@B10]\] and the DGFS scoring system\[[@B11]\] to predict delayed graft function. The cold ischemia time (purple-line): Area under ROC curve (AUC) = 0.52. The DGF risk calculator (green-line) proposed by Irish et al\[[@B9]\]: AUC = 0.69. The scoring system (blue-line) proposed by Jeldres et al\[[@B10]\]: AUC = 0.54. The DGFS scoring system (red-line) proposed by Chapal et al\[[@B11]\]: AUC = 0.51. ROC: Receiver operating characteristic; CIT: Cold ischemia time; DGF: Delayed graft function.](WJT-7-260-g001){#F1}

![Calibration plot of: The delayed graft function risk calculator (Irish et al\[[@B9]\]), the Jeldres scoring system\[[@B10]\] and the DGFS scoring system (Chapal et al\[[@B11]\]) to predict delayed graft function. Patients were divided into 10 subgroups (deciles of increased DGF risk), based upon the risk prediction. Each figure plots the mean predicted probability (X-axis) of DGF against the observed prevalence of DGF (Y-axis) (Hosmer-Lemeshow). The *P*-values were 0.74 for the Irish score, \< 0.05 for the Jeldres score and 0.02 for the Chapal score. DGF: Delayed graft function.](WJT-7-260-g002){#F2}

![Correlation between the predicted delayed graft function probability according to the delayed graft function risk calculator (Irish et al\[[@B9]\]) and the presence or absence of delayed graft function. DGF: Delayed graft function.](WJT-7-260-g003){#F3}

Analysis according to the algorithm of Jeldres et al\[[@B10]\]
--------------------------------------------------------------

At the population level, the average DGF risk calculated with Jeldres nomogram was 27.9%, which is almost the double of the observed DGF rate (15.3%). The AUC of the ROC curve was poor at 0.54 (Figure [1](#F1){ref-type="fig"}). The Hosmer-Lemeshow "goodness-of-fit" test demonstrated a significant difference (*P* \< 0.05) between the predicted DGF risk and the observed DGF, which indicates that the DGF risk was not well estimated by the Jeldres scoring system (Figure [2B](#F2){ref-type="fig"}). The calculated risk of DGF showed a wide range of values from 5%-82% in the DGF-group and 3%-83% in the non- DGF-group with a very large overlap between both groups (Figure [4](#F4){ref-type="fig"}). The sensitivity, specificity and positive predictive value of a calculated DGF risk ≥ 30% was 44.7%, 61.7% and 17.5% respectively.

![Correlation between the predicted delayed graft function probability according to the Jeldres scoring system (Jeldres et al\[[@B10]\]) and the presence or absence of delayed graft function. DGF: Delayed graft function.](WJT-7-260-g004){#F4}

Analysis according to the algorithm of Chapal et al\[[@B11]\]
-------------------------------------------------------------

The average DGFS value was -0.48 \[(-0.46) ± 0.76; 95%CI: (-0.43) - (-0.71)\] in the DGF positive group and (-0.48) ± 0.89; 95%CI: (-0.46) - (-0.60) in the DGF negative group\] (Figure [5A](#F5){ref-type="fig"}), indicating the inability of the Chapal score to predict DGF in our population. The sensitivity, specificity and negative predictive value of a DGFS value ≤ (-0.5) were 45.6%, 70.3% and 85.8% respectively. Only 3 patients (1.2%) had a DGFs score ≥ 1.2, which should in theory point to a high risk of DGF. None of these 3 patients developed DGF (sensitivity and positive predictive value for DGFs score ≥ 1.2 was 0).

![Correlation between the DGFS value (A: Y-axis) and the predicted delayed graft function probability according to the DGFS scoring system (Chapal et al\[[@B11]\]) (B: Y-axis) and the presence or absence of delayed graft function (A and B: X-axis). DGF: Delayed graft function.](WJT-7-260-g005){#F5}

The average DGF risk calculated with the DGFS nomogram was 20%. The ROC curve analysis showed a c-index of 0.51 (Figure [1](#F1){ref-type="fig"}), indicating the absence of any predictive value. There was no difference between the median calculated DGF risk in the DGF-positive and the DGF-negative subjects (Figure [5B](#F5){ref-type="fig"}). The calibration plot of this model (Figure [2C](#F2){ref-type="fig"}) showed a significant difference (*P* = 0.02) between the predicted DGF risk and the observed DGF, which indicates that the DGF risk was not well calibrated by the Chapal nomogram. The sensitivity, specificity and positive predictive value of a calculated DGF risk ≥ 30% were 5.2%, 88% and 8% respectively.

Analysis in the subgroups with a higher risk of DGF
---------------------------------------------------

Next, we studied how well the three nomograms can predict DGF in subgroups of patients considered to be at increased risk of DGF such as ECD and DCD donors (Table [4](#T4){ref-type="table"}). The results presented in Table [4](#T4){ref-type="table"} suggest an acceptable agreement between the observed prevalence of DGF and the Irish DGF score for DCD donors, but not for ECD donors. The DGFS scoring system and the Jeldres scoring system\[[@B10]\] could not predict DGF in these high-risk groups (Table [4](#T4){ref-type="table"}).

###### 

Observed prevalence *vs* predicted probability of delayed graft function in the overall population and by risk group

  **Kidney graft according to donor type**   **Observed prevalence of DGF (%)**          **Probability of DGF predicted by the DGF risk calculator (%) (Irish et al\[[@B9]\])**   **Probability of DGF predicted by the DGF scoring system (%) (Chapal et al\[[@B11]\])**   **Probability of DGF predicted by the Jeldres scoring system (%) (Jeldres et al\[[@B10]\])**
  ------------------------------------------ ------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Overall population (*n* = 247)             15.3                                        16[1](#T4FN1){ref-type="table-fn"}                                                       19.7[1](#T4FN1){ref-type="table-fn"}                                                      25[1](#T4FN1){ref-type="table-fn"}
  12-24[2](#T4FN2){ref-type="table-fn"}      13.6-26[2](#T4FN2){ref-type="table-fn"}     14-40[2](#T4FN2){ref-type="table-fn"}                                                                                                                                              
  0.69[3](#T4FN3){ref-type="table-fn"}       0.51[3](#T4FN3){ref-type="table-fn"}        0.54[3](#T4FN3){ref-type="table-fn"}                                                                                                                                               
  Standard criteria donor (*n* = 170)        11.8                                        14[1](#T4FN1){ref-type="table-fn"}                                                       20.1[1](#T4FN1){ref-type="table-fn"}                                                      21[1](#T4FN1){ref-type="table-fn"}
  10-20[2](#T4FN2){ref-type="table-fn"}      14.5-26.4[2](#T4FN2){ref-type="table-fn"}   13.7-34.2[2](#T4FN2){ref-type="table-fn"}                                                                                                                                          
  0.73[3](#T4FN3){ref-type="table-fn"}       0.60[3](#T4FN3){ref-type="table-fn"}        0.54[3](#T4FN3){ref-type="table-fn"}                                                                                                                                               
  Extended criteria donor (*n* = 42)         19                                          19.5[1](#T4FN1){ref-type="table-fn"}                                                     21.2[1](#T4FN1){ref-type="table-fn"}                                                      41.5[1](#T4FN1){ref-type="table-fn"}
  14-25[2](#T4FN2){ref-type="table-fn"}      14.4-27.6[2](#T4FN2){ref-type="table-fn"}   25.7-60[2](#T4FN2){ref-type="table-fn"}                                                                                                                                            
  0.39[3](#T4FN3){ref-type="table-fn"}       0.34[3](#T4FN3){ref-type="table-fn"}        0.38[3](#T4FN3){ref-type="table-fn"}                                                                                                                                               
  Donation after cardiac death (*n* = 35)    28.6                                        30[1](#T4FN1){ref-type="table-fn"}                                                       11.8[1](#T4FN1){ref-type="table-fn"}                                                      21[1](#T4FN1){ref-type="table-fn"}
  18-38[2](#T4FN2){ref-type="table-fn"}      9.1-20.4[2](#T4FN2){ref-type="table-fn"}    8-39[2](#T4FN2){ref-type="table-fn"}                                                                                                                                               
  0.65[3](#T4FN3){ref-type="table-fn"}       0.58[3](#T4FN3){ref-type="table-fn"}        0.64[3](#T4FN3){ref-type="table-fn"}                                                                                                                                               

Median;

P25-P75;

AUC of the ROC curve. DGF: Delayed graft function.

DISCUSSION
==========

The first finding from our study is that our mean DGF rate was in the low range (15%), with a stepwise increase according to the risk categories (SCD, ECD, DCD donors). Next, we found that, at a population level, the observed DGF rate and the median calculated DGF risk according to the Irish calculator (16%) were similar. In our study the AUC calculated according to the Irish calculator was 0.69 which is similar to the results obtained in the 2010 Irish model (AUC of 0.70) and indicates an acceptable degree of discrimination. Along this line, the Hosmer-Lemeshow "goodness-of-fit" test demonstrated that the DGF risk was well calibrated by the DGF risk calculator. With regards to the ECD and DCD high-risk groups, there was a good agreement for DCD but not for ECD. This could be due to the smaller number of patients tested with these conditions in our center. While it appears that the DGF risk calculator can relatively well predict the percentage of DGF in our global study group, it is obvious that we cannot use this tool to take clinical decisions for individual patients. Indeed, as seen in Figure [3](#F3){ref-type="fig"}, because of the large overlap in DGF risk prediction between patients who developed DGF and those who did not, a high- or low-risk score did not correspond with the presence or absence of DGF. The specificity, sensitivity and positive predictive value of the DGF-risk calculator are too low to help with clinical-decision making regarding the immunosuppressive strategy. This nomogram has been previously tested in Australian\[[@B8]\], North American\[[@B16]\] and European\[[@B17]\] populations, but yielded conflicting results. In the Australian cohort from Kaisar et al\[[@B8]\] the nomogram was applied to 598 deceased donor renal transplantations, and showed a slightly better AUC value of 0.76 with a sensitivity of 74% and a specificity of 71%. Of note, however, no data are given about the overlap between the DGF and no DGF patients in this series, and it is thus difficult to evaluate its predictive value at individual patient level. Moore et al\[[@B17]\] evaluated the nomogram of Irish on 210 United Kingdom patients and showed a similar predictive value with an AUC of 0.71 with a high specificity (95%) but a very poor sensitivity (25%) at a score \> 150. They concluded that the utility of the nomogram score in predicting DGF was moderate at best. Grossberg et al\[[@B16]\] showed a poor association between the Irish nomogram and DGF (the average DGF risk in DGF-positive patients was 0.45 ± 0.14 *vs* 0.40 ± 0.14 in DGF-negatives, *P* = 0.07) in a US population of 169 patients, but they did not report a c-index.

In 2012, Rodrigo et al\[[@B18]\], used the web-based calculator to predict DGF on 342 European renal transplants. Similar to the Irish group\[[@B9]\] they found an AUC of 0.71. The reported specificity and sensitivity of a calculated DGF risk ≥ 30% were 75.8% and 51.8% respectively. They concluded, like us, that there was overlap in DGF risk prediction, which limited the utility of the score for individual patients. Finally, a large number of variables are needed to calculate the Irish DGF risk score, which limits its usefulness in daily clinical practice.

For this particular reason, two other independent and easier scoring systems were developed\[[@B10],[@B11]\]. Jeldres et al\[[@B10]\] developed a more user-friendly nomogram based on the analysis of 6 risk factors. The c-statistic for assessing the predictive ability of Jeldres score for DGF (internal validation) was very similar to the Irish scoring system (AUC of 0.74). However, Chapal et al\[[@B11]\] tried to validate Jeldres score on their patients and showed an inferior predictive capacity of this scoring system to predict DGF (AUC = 0.61). The ROC curve analysis based on our population showed that the predictive utility of the Jeldres scoring system was poor, with a c-index of 0.54. This poor predictive value was confirmed by the Hosmer-Lemeshow "goodness-of-fit" test that showed a bad calibration of this model. The median calculated DGF risk in the DGF-positive group did not differ significantly from the DGF-negative group and there was a large overlap between both groups. Jeldres et al\[[@B10]\] proposed no cut-off to classify patients according to their DGF risk in their original study.

In our study the predictive capacity of the DGFS scoring system from Chapal was poor with an AUC of 0.51. In our population the negative predictive value of the DGFS score was 0.86 which implies that with the DGFS scoring system we can fairly well recognize the patients at a low risk of DGF. In contrast, the threshold for high risk of DGF was clinically useless in our study (none of the patients with DGFS score ≥ 1.2 actually developed DGF). The failure of the DGFS scoring system in the prediction of DGF in our study may be explained by a lower incidence of DGF in our population (15.3% in our study *vs* 25.5% in the study of Chapal et al\[[@B11]\]). This difference is the consequence of shorter CIT \[14 h (range 2.8 to 29.9 h) *vs* 19.2 h (range 6.0 to 58.6 h)\], use of kidneys from younger donors (45.1 years *vs* 51.9 years) and lower terminal donor serum creatinine (69 μmol/L *vs* 91 μmol/L) in respectively our study population and in the study by Chapal\[[@B11]\]. According to these data our center seems to be more stringent in the selection of donors. This could also explain why the algorithm proposed by Chapal et al\[[@B11]\] fails to predict adequately DGF in our population.

There are some limitations to our study. First, the need to dialyse within the first week after the transplantation is an endpoint that could be influenced by several clinical factors (such as for instance heart failure, hyperkalemia...). This can lead to obvious mistakes in the validation of different scoring systems. Second, the sample size in our study is relatively small, particularly when compared to large-population-based transplant registers. Finally, the composition of our study population differs from the initial studies \[*e.g*., 4.5% blacks in our population *vs* 30.1% blacks in the study of Irish; relatively short CIT in our study (14 ± 4.7 h *vs* 19.2 ± 7 h in the study of Chapal or 17.8 ± 7.8 h in the study of Irish)\]. And finally, according to our induction immunosuppression protocols ATG was de facto given to the patients at increased risk for DGF. The delayed introduction of CNIs could have attenuated the incidence of DGF in our population at risk. Another issue not captured by any scoring system is the policy of peri-operative volemia control, which has been shown to play an important role in the incidence of DGF (Mikhalski et al\[[@B4]\]).

In summary, our study suggests that currently available predictive models for the risk of DGF after kidney transplantation are predictive in the population in which they were derived, but they lose their predictive value in external validations. This is not surprising, as none of these scores has been previously rigorously validated in external population of patients. Along this line, there were large variations between centers regarding demographic values (donor age, CIT, proportion of ECD/DCD, *etc*...) explaining why external validation like the one we tried, failed. This means that we still need better predictive tools for the kidney allocation to individual patients, especially those patients who are at high risk of DGF. Currently we are unable to further improve the outcome of a single patient by altering our management on the basis of available scores for the risk of DGF.

COMMENTS
========

Background
----------

Delayed graft function (DGF) occurs in 10% to 40% of deceased donor kidney transplantations, and leads to prolonged hospitalization, higher costs of transplantation, and increased complexity of management of immunosuppressive drugs. The ability to predict DGF at the time of the transplant offer might help in clinical decision making, such as declining the offer, selecting a recipient who would have a lower DGF risk, or modifying the transplantation strategy. Three predictive scoring systems for DGF were previously developed and published (Irish et al, Jeldres et al and Chapal et al). However, since these scores were not validated in an external study population, we decided to analyse the performance of these three scoring systems in a single centre cohort of 247 consecutive kidney transplant recipients at our institution between 2003 and 2013.

Research frontiers
------------------

Three different scoring systems for the prediction of DGF have been developed and validated in the past in respectively well-defined study populations, specific for each study. However, these scoring systems were never validated in an external study population (*i.e*., different from the initial study population). To explore the validity of these three predictive models, we retrospectively analysed their performance in a cohort of 247 consecutive kidney transplant recipients at our institution.

Innovations and breakthroughs
-----------------------------

DGF occurred in 15% of this study population. Only the Irish calculator provided an acceptable level of prediction for DGF with an AUC of the ROC curve of 0.69. However, at the level of the individual patient the calculated risk of DGF overlapped very widely, and therefore this predictive score was not useful in clinical decision making in our study population.

Applications
------------

Based on the reported literature and on our data, we conclude that predictive models for DGF are performant in the population in which they were derived, but these models require additional validation in an external study population.

Terminology
-----------

DGF: Delayed graft function; AUC: Area under the curve; ROC: Receiver operator curve; C index: The index of concordance is a "global" index for validating the predictive ability of an algorithm (*e.g*., for the occurrence of DGF); Nomogram: Is a prediction tool based on information from large numbers of patients. Predictive data are put in a mathematical model that enables to calculate a hypothetical outcome measure.

Peer-review
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It is very well-conducted study with some interesting findings, mostly pointed out that we still cannot predict with accuracy the development of DGF. The study design and method, and statistical analysis were all well-thought and accurately followed throughout the paper.
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